Interferon Alpha Plus 13-Cis-Retinoic Acid Modulation of BCL-2 Plus Paclitaxel for Recurrent Small Cell Lung Cancer (SCLC): An Eastern Cooperative Oncology Group Study (E6501)

BACKGROUND: Patients with recurrent small cell lung cancer (SCLC) have dismal outcomes. The failure of salvage therapy is due to the possible development of resistance mechanisms, such as the upregulation of the anti-apoptosis protein, Bcl-2. We conducted a phase II study to evaluate if modulation o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Chemother Pharmacol
Autors principals: Pillai, Rathi N., Aisner, Joseph, Dahlberg, Suzanne E., Rogers, John S., DiPaola, Robert S., Aisner, Seena, Ramalingam, Suresh S., Schiller, Joan H.
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4296897/
https://ncbi.nlm.nih.gov/pubmed/24858462
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-014-2427-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars